全文获取类型
收费全文 | 2965篇 |
免费 | 162篇 |
国内免费 | 31篇 |
学科分类
医药卫生 | 3158篇 |
出版年
2023年 | 18篇 |
2022年 | 13篇 |
2021年 | 63篇 |
2020年 | 40篇 |
2019年 | 49篇 |
2018年 | 60篇 |
2017年 | 52篇 |
2016年 | 70篇 |
2015年 | 86篇 |
2014年 | 84篇 |
2013年 | 142篇 |
2012年 | 210篇 |
2011年 | 170篇 |
2010年 | 113篇 |
2009年 | 102篇 |
2008年 | 175篇 |
2007年 | 191篇 |
2006年 | 187篇 |
2005年 | 184篇 |
2004年 | 148篇 |
2003年 | 159篇 |
2002年 | 139篇 |
2001年 | 54篇 |
2000年 | 62篇 |
1999年 | 34篇 |
1998年 | 39篇 |
1997年 | 25篇 |
1996年 | 27篇 |
1995年 | 25篇 |
1994年 | 24篇 |
1993年 | 13篇 |
1992年 | 38篇 |
1991年 | 33篇 |
1990年 | 33篇 |
1989年 | 28篇 |
1988年 | 31篇 |
1987年 | 20篇 |
1986年 | 18篇 |
1985年 | 21篇 |
1984年 | 19篇 |
1983年 | 13篇 |
1982年 | 11篇 |
1981年 | 11篇 |
1979年 | 18篇 |
1975年 | 9篇 |
1974年 | 13篇 |
1973年 | 9篇 |
1972年 | 10篇 |
1971年 | 10篇 |
1967年 | 9篇 |
排序方式: 共有3158条查询结果,搜索用时 21 毫秒
1.
Elisa Giani Andrea Enzo Scaramuzza Gian Vincenzo Zuccotti 《World journal of diabetes》2015,6(8):999-1004
Technologies for diabetes management, such as continuous subcutaneous insulin infusion (CSII) and continuous glucose monitoring (CGM) systems, have improved remarkably over the last decades. These developments are impacting the capacity to achieve recommended hemoglobin A1c levels and assisting in preventing the development and progression of micro- and macro vascular complications. While improvements in metabolic control and decreases in risk of severe and moderate hypoglycemia have been described with use of these technologies, large epidemiological international studies show that many patients are still unable to meet their glycemic goals, even when these technologies are used. This editorial will review the impact of technology on glycemic control, hypoglycemia and quality of life in children and youth with type 1 diabetes. Technologies reviewed include CSII, CGM systems and sensor-augmented insulin pumps. In addition, the usefulness of advanced functions such as bolus profiles, bolus calculators and threshold-suspend features will be also discussed. Moreover, the current editorial will explore the challenges of using these technologies. Indeed, despite the evidence currently available of the potential benefits of using advanced technologies in diabetes management, many patients still report barriers to using them. Finally this article will highlight the importance of future studies tailored toward overcome these barriers to optimizing glycemic control and avoiding severe hypoglycemia. 相似文献
2.
Stefano Di Domenico Giulio Bovio Maximiliano Gelli Ferruccio Ravazzoni Enzo Andorno Damiano Cottalasso Umberto Valente 《BMC surgery》2007,7(1):18
Background
Liver transplantation in presence of diffuse portal vein thrombosis is possible by using caval blood as portal inflow, through cavo-portal transposition. However, clinical results are heterogeneous and experimental studies are needed, but similar hemodynamic conditions are difficult to obtain, especially in small animals. Herein we describe a new simple model of cavo-portal transposition in rat. 相似文献3.
4.
A. Tentorio G. Ghilardi A. Pedroncelli R. Benco S. Stroppa S. Adib D. Gianola G. Pagani 《European journal of clinical pharmacology》1989,36(3):311-313
Summary The effect of nifedipine 40 mg·day–1 for 3 months on glucose tolerance, insulin and C-peptide secretion after an oral glucose tolerance test (OGTT), intra-venous glucose tolerance test (IVGTT) and glucagon stimulatory test, has been studied in 8 moderately hypertensive women suffering from non-insulin dependent diabetes mellitus (NIDDM).No significant variation in glucose metabolism was noted after nifedipine treatment, except for a slight improvement in insulin secretion after OGTT at the end of the study. There was an increase in cholesterol as a collateral effect. 相似文献
5.
6.
Devang N Patel Francis D Pagani Todd M Koelling David B Dyke Ragavendra R Baliga Robert J Cody Kathleen D Lake Keith D Aaronson 《The Journal of heart and lung transplantation》2002,21(2):204-210
BACKGROUND: Pravastatin and simvastatin prolong survival and reduce transplant-related coronary vasculopathy, although low-density lipoprotein (LDL) lowering with these agents is only modest. The objective of this study was to assess the safety of moderate dose atorvastatin and its efficacy when prior treatment with another statin had failed to lower LDL to < 100 mg/dl. METHODS: Data from 185 patients were retrospectively evaluated for adverse events, duration of exposure (person-days), and the mean atorvastatin dose exposure. Changes in lipid parameters, and prednisone and cyclosporine doses were determined. RESULTS: Safety: 48 patients received atorvastatin for 24,240 person-days at a mean dose exposure of 21 +/- 10 mg. Rhabdomyolysis, myositis, myalgias, and hepatotoxicity occurred in 0, 2, 2, and 0 patients, respectively. All events occurred at the 10-mg dose, within the first 3 months, and were rapidly reversible with atorvastatin discontinuation. Efficacy: Thirty-four patients evaluable for efficacy analyses had a pre-atorvastatin LDL of 145 +/- 38 mg/dl on the following statins: pravastatin (n = 30, 40 +/- 0mg), fluvastatin (n = 3, 33 +/- 12 mg), simvastatin (n = 1, 40 mg). After atorvastatin (21 +/- 9 mg/day) for 133 +/- 67 days, LDL was reduced to 97 +/- 24 mg/dl (relative reduction 31 +/- 20%, p < 0.0001). At the end of the observation period (418 +/- 229 days, atorvastatin final dose 24 +/- 14 mg/day), LDL was further decreased to 88 +/- 23 mg (relative reduction 37 +/- 17%, p < 0.0001). CONCLUSION: Atorvastatin, when used at moderate doses and with close biochemical and clinical monitoring, appears to be safe and is effective in aggressively lowering LDL in heart transplant recipients when treatment with other statins has failed to achieve LDL goals. 相似文献
7.
8.
Claudio Baracchini Enzo Ballotta 《Journal of endovascular therapy》2004,11(6):749-50; author reply 750-1
9.
A. Pagani G. Ippoliti P. Perseghin C. Origlia L. Salvaneschi 《Annals of hematology》1988,56(3):103-105
Summary An unusual case of chronic myelocytic leukemia (CML) is described that presented leukocytosis at onset (720×109/l), symptoms of stasis, organomegaly, and a conspicuous infiltration of leukemic cells from the pelvis to the right popliteal cavity. As initial therapy and in addition to chemotherapy, six therapeutic leukapheresis treatments (TL) were performed and the patient showed dramatic symptomatic improvement with reduction in leukocytosis (97×109/l), organomegaly, and tissue infiltration. 相似文献
10.
R Pagani M T Portolés I Díaz-Laviada A M Municio 《British journal of experimental pathology》1988,69(4):537-549
Lipopolysaccharides (LPS) from Gram-negative bacteria are considered to be the responsible agents for the induction of endotoxic shock, affecting the liver as a target organ. In this study, the cell morphology and some biochemical properties of 24 h-culture-hepatocyte monolayers treated with Escherichia coli 0111:B4 lipopolysaccharide, were observed. Cell morphology was observed by scanning electron microscopy and immunofluorescence methods. LPS interaction induced an increase in rounded cells with diminished adhesion capacity. As biochemical parameters, albumin synthesis and 2-deoxyglucose uptake were measured. LPS decreased the hexose uptake in a dose-dependent manner. Binding of (14C)LPS to cultured hepatocytes showed that LPS binds to non-specific constituents of the membrane bilayer. 相似文献